Mark Glassy - Nascent Biotech Chairman
| NBIO Stock | USD 0.05 0.0004 0.74% |
Chairman
Dr. Mark Glassy serves as Chief Science Officer, Director of the Company. He is the Chairman, Chief Science Officer of Nascent Biotech and the Director and Professor at the Integrated Medical Science Association Foundation since 2014.
| Age | 71 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Phone | 612 961 5656 |
| Web | https://www.nascentbiotech.com |
Nascent Biotech Management Efficiency
The company has return on total asset (ROA) of (0.885) % which means that it has lost $0.885 on every $100 spent on assets. This is way below average. Nascent Biotech's management efficiency ratios could be used to measure how well Nascent Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| Garo Armen | Protagenic Therapeutics | 71 | |
| Eric Weisblum | Silo Pharma | 54 | |
Management Performance
| Return On Asset | -0.88 |
Nascent Biotech Leadership Team
Elected by the shareholders, the Nascent Biotech's board of directors comprises two types of representatives: Nascent Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nascent. The board's role is to monitor Nascent Biotech's management team and ensure that shareholders' interests are well served. Nascent Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nascent Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lowell Holden, CFO, Chief Accounting Officer and Director | ||
| Mark Glassy, Chief Science Officer and Chairman of Scientific Advisory Board | ||
| Sean Carrick, President, Secretary and Director | ||
| Navpaul MD, Chief Consultant |
Nascent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Nascent Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.88 | |||
| Profit Margin | (1.25) % | |||
| Operating Margin | (0.92) % | |||
| Current Valuation | 21.83 M | |||
| Shares Outstanding | 119.56 M | |||
| Shares Owned By Insiders | 31.85 % | |||
| Shares Owned By Institutions | 0.80 % | |||
| Price To Earning | 66.00 X | |||
| Price To Book | 6.91 X | |||
| Price To Sales | 21.78 X |
Pair Trading with Nascent Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nascent Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nascent Biotech will appreciate offsetting losses from the drop in the long position's value.Moving against Nascent OTC Stock
| 0.57 | NONOF | Novo Nordisk AS | PairCorr |
| 0.55 | NVO | Novo Nordisk AS | PairCorr |
| 0.54 | REGN | Regeneron Pharmaceuticals | PairCorr |
| 0.47 | QSAM | Qsam Biosciences | PairCorr |
| 0.37 | CSLLY | CSL | PairCorr |
The ability to find closely correlated positions to Nascent Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nascent Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nascent Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nascent Biotech to buy it.
The correlation of Nascent Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nascent Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nascent Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nascent Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Nascent OTC Stock
Nascent Biotech financial ratios help investors to determine whether Nascent OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nascent with respect to the benefits of owning Nascent Biotech security.